Novartis Battens Down Hatches Over Falsified Zolgensma Data
The Swiss major believes it responded in a timely fashion to data manipulation issues associated with its closely watched gene therapy but CEO Vas Narasimhan's bid to rebuild trust with society has taken a hit.
You may also be interested in...
The roller coaster ride for Novartis with its high-profile gene therapy Zolgensma continues as the FDA places a partial hold on trials of an intrathecal version aimed at older SMA patients on the back of nerve inflammation seen in a preclinical study.
Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.
The Swiss major has new data on its SMA gene therapy which has been found not to be the cause of the death of a six-month-old patient earlier this year.